--- title: "BioAtla (BCAB) news: offering" url: "https://aibio.space/companies/bioatla/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BCAB offering news: BioAtla agrees to about $9.2 million registered direct offering at $0.9520. BioAtla, Inc. (OTC: BCAB), United States." --- BCAB BioAtla, Inc. OTC · United States # BioAtla (BCAB) news BCAB offering news Financings · 2026-10-20 ## [BioAtla signs $40.0 million standby equity deal with Yorkville](https://aibio.space/news/bioatla-signs-40-0-million-standby-equity-deal-yorkville/) BioAtla can sell up to $40.0 million of stock to Yorkville over 36 months, but its cash was $1.5 million at June 30, 2026, and its prior $15.0 million line raised about $0.4 million. ## Latest BioAtla news 1. 2025-09-22 Listings [BioAtla wins Nasdaq panel extension with deadlines to fix price and equity gaps](https://aibio.space/news/bioatla-wins-nasdaq-panel-extension-deadlines-fix-price-equity-gaps/) A Nasdaq hearing panel let BioAtla stay listed on conditions: a transfer to the Nasdaq Capital Market by September 26, 2025, equity compliance by December 31, 2025 and bid price compliance by February 2, 2026. 2. 2024-12-20 Financings [BioAtla agrees to about $9.2 million registered direct offering at $0.9520](https://aibio.space/news/bioatla-agrees-about-9-2-million-registered-direct-offering-0-9520/) BioAtla is selling 9,679,158 shares with warrants at a combined $0.9520 each, through sole placement agent Tungsten Advisors, for about $9.2 million gross and about $8.5 million net. ## BioAtla at a glance - **Ticker**: BCAB - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $1.5 million ### Related companies - [Jade Biosciences](https://aibio.space/companies/jade-biosciences/) NASDAQ: JBIO - [Unicycive Therapeutics](https://aibio.space/companies/unicycive-therapeutics/) NASDAQ: UNCY - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) NASDAQ: BDTX - [Recursion Pharmaceuticals](https://aibio.space/companies/recursion-pharmaceuticals/) NASDAQ: RXRX - [Exicure](https://aibio.space/companies/exicure/) NASDAQ: XCUR - [Marker Therapeutics](https://aibio.space/companies/marker-therapeutics/) NASDAQ: MRKR - [Aspira Women's Health](https://aibio.space/companies/aspira-women-s-health/) OTC: AWHL - [Calidi Biotherapeutics](https://aibio.space/companies/calidi-biotherapeutics/) AMEX: CLDI ### Also on OTC - [MabCure](https://aibio.space/companies/mabcure/) MBCI - [Green Planet Bio Engineering Co.](https://aibio.space/companies/green-planet-bio-engineering/) GPLB - [Halberd](https://aibio.space/companies/halberd/) HALB - [Zivo Bioscience](https://aibio.space/companies/zivo-bioscience/) ZIVO - [Viskase Holdings](https://aibio.space/companies/viskase/) VISK - [SKYTECH ORION GLOBAL CORP.](https://aibio.space/companies/skytech-orion-global/) SKTG ## BioAtla annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$43.6 million](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134499/) | [$63.1 million](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134499/) | | Net income (loss) | [-$59.6 million](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134499/) | [-$69.8 million](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134499/) | | Cash from operations | [-$48.2 million](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134499/) | [-$71.9 million](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134499/) | | Cash and equivalents | [$7.1 million](https://www.sec.gov/Archives/edgar/data/1826892/000119312526349542/) | [$49.0 million](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134499/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BioAtla Has BioAtla raised money recently? Our latest story on this, dated Dec 20, 2024: "BioAtla agrees to about $9.2 million registered direct offering at $0.9520". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/bioatla-agrees-about-9-2-million-registered-direct-offering-0-9520/). What is the ticker symbol of BioAtla? BioAtla, Inc. trades under the ticker BCAB on OTC. Where is BioAtla listed? BioAtla, Inc. is listed on OTC. What is the SEC CIK of BioAtla? The SEC Central Index Key (CIK) for BioAtla, Inc. is 1826892. Its filings are on SEC EDGAR. How many shares does BioAtla have outstanding? 32,315,301 shares as of 2021-08-13, per the cover page of its 10-Q filed 2021-08-13. Which country or territory is BioAtla listed under? Our directory records BioAtla, Inc. under United States. What does BioAtla do? Our directory classifies BioAtla, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of BioAtla? The ISIN recorded for BioAtla, Inc. is US09077B2034. Does aibio.space cover BioAtla? aibio.space lists BioAtla, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is BioAtla incorporated? SEC records list its state or country of incorporation as DE. Is BioAtla profitable? BioAtla, Inc. reported a net loss of $59.6 million for the fiscal year ended Dec 31, 2025, and used $48.2 million of cash in operations, per its annual report to the SEC. How much does BioAtla spend on research and development? $43.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does BioAtla have? $1.5 million in cash at Jun 30, 2026, per its 10-Q. What is the latest BioAtla (BCAB) stock news? Our latest story on BioAtla, dated Oct 20, 2026: "BioAtla signs $40.0 million standby equity deal with Yorkville". BioAtla can sell up to $40.0 million of stock to Yorkville over 36 months, but its cash was $1.5 million at June 30, 2026, and its prior $15.0 million line raised about $0.4 million. [Source](https://aibio.space/news/bioatla-signs-40-0-million-standby-equity-deal-yorkville/). How long will BioAtla's cash last? From our story of Sep 22, 2025: The 8-K's forward-looking statements list factors that raise substantial doubt about the company's ability to continue as a going concern, along with the need for additional funding to continue development of its CAB technology platform and product candidates. [Source](https://aibio.space/news/bioatla-wins-nasdaq-panel-extension-deadlines-fix-price-equity-gaps/). ## Investor discussion: BioAtla Members talk about BioAtla (BCAB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BioAtla, newest first. Each line links the filing it comes from. 1. 2026-10-20 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312526425553/bcab-20261015.htm) 2. 2026-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000153949726002373/n5620_x8-8k.htm) 3. 2026-03-31 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134501/bcab-ex99_1.htm) 4. 2026-03-02 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000153949726000812/exh99_1.htm) 5. 2026-02-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312526041367/bcab-20260206.htm) 6. 2026-01-30 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312526031942/bcab-20260126.htm) 7. 2026-01-30 Mergers Reported a merger or acquisition agreement. SEC Form PREM14A. [Source](https://www.sec.gov/Archives/edgar/data/1826892/000153949726000230/n5620_x1-prem14a.htm) 8. 2026-01-12 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.02,5.03,5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312526010458/bcab-20260109.htm) 9. 2025-12-31 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/d20340dex991.htm) 10. 2025-12-30 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312525337078/bcab-20251230.htm) 11. 2025-12-05 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1826892/000153949725003176/n5452_x1-def14a.htm) 12. 2025-11-24 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312525292058/d830876dpre14a.htm) 13. 2025-11-21 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312525290474/bcab-20251120.htm) 14. 2025-09-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312525211305/bcab-20250916.htm) 15. 2025-05-16 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000095017025073688/bcab-20250512.htm) 16. 2025-03-28 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1826892/000095017025046217/bcab-20241231.htm) 17. 2025-03-27 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000095017025046065/bcab-ex99_1.htm) 18. 2025-02-07 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000095017025016321/bcab-20250206.htm) 19. 2024-12-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1826892/000119312524283212/d823541dex991.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:BCAB on TradingView](https://www.tradingview.com/symbols/OTC-BCAB/). ## SEC filings and registration - **SEC name**: BioAtla, Inc. - **CIK**: 1826892 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: BCAB (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 11085 TORREYANA ROAD, SAN DIEGO, CA, 92121 - **Phone**: 858-558-0708 - **Shares outstanding**: 32,315,301 as of 2021-08-13 (10-Q filed 2021-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [S-1](https://www.sec.gov/Archives/edgar/data/1826892/000153949726002711/n5620_x9-s1.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1826892/000119312526425553/bcab-20261015.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1826892/000119312526407817/bcab-20260923.htm) filed 2026-09-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1826892/000153949726002373/n5620_x8-8k.htm) filed 2026-08-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1826892/000119312526349542/bcab-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1826892/000119312526306117/bcab-20260716.htm) filed 2026-07-16 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1826892/000119312526255422/bcab-20260603.htm) filed 2026-06-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/1826892/000119312526226631/bcab-20260331.htm) filed 2026-05-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001826892), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BioAtla, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker BCAB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BioAtla, Inc. - **Ticker**: BCAB - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US09077B2034 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-BCAB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/bioatla/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioAtla (BCAB) news: offering", 2026-10-31, https://aibio.space/companies/bioatla/